No abstract available
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminopyridines
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Apoptosis / drug effects
-
Benzamides
-
Blotting, Western
-
Cell Proliferation / drug effects
-
Drug Resistance, Neoplasm / drug effects*
-
Fusion Proteins, bcr-abl / antagonists & inhibitors*
-
Fusion Proteins, bcr-abl / genetics
-
Fusion Proteins, bcr-abl / metabolism
-
Humans
-
Imatinib Mesylate
-
Leukemia, Experimental / drug therapy
-
Leukemia, Experimental / metabolism
-
Leukemia, Experimental / pathology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Mice
-
Mice, Nude
-
Phosphorylation / drug effects
-
Piperazines / pharmacology*
-
Protein Kinase Inhibitors / pharmacology*
-
Proto-Oncogene Proteins c-kit / metabolism
-
Pyridines / pharmacology*
-
Pyrimidines / pharmacology*
-
RNA, Messenger / genetics
-
Receptor, Platelet-Derived Growth Factor beta / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
-
Survival Rate
-
Tumor Cells, Cultured
-
Xenograft Model Antitumor Assays
Substances
-
Aminopyridines
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyridines
-
Pyrimidines
-
RNA, Messenger
-
Imatinib Mesylate
-
Proto-Oncogene Proteins c-kit
-
Receptor, Platelet-Derived Growth Factor beta
-
Fusion Proteins, bcr-abl
-
flumatinib